Study of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age

Iroko Pharmaceuticals

Status and phase

Completed

Phase 2

Conditions

Pain, Postoperative

Treatments

Drug: Diclofenac Capsules high dose

Drug: Diclofenac Capsules low dose

Study type

Interventional

Funder types

Industry

Identifiers

NCT02424578

DIC2-14-08

Details and patient eligibility

About

The purposes of this study are to evaluate the safety and tolerability and to model the single-dose pharmacokinetic profile of diclofenac capsules low dose and high dose in children ages 6 to <17 years experiencing mild to moderate acute postoperative pain.

Enrollment

30 patients

Sex

All

Ages

6 to 16 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Body weight ≥18 kilograms.
Mild to moderate acute pain requiring treatment with analgesic medication.
Willing to have blood samples taken for PK sampling using an indwelling catheter.
Must be able to swallow capsules and can tolerate oral medication.
For females: is not of reproductive potential (defined as premenarchal) or is practicing an acceptable method of birth control

Exclusion criteria

Severe acute pain
Chronic analgesic or glucocorticoid use for any condition within 6 months before dosing with study drug.
Emergency surgery
History of allergic reaction, hypersensitivity, or clinically significant intolerance to diclofenac, aspirin, codeine, acetaminophen, or any NSAID
History of peptic ulcer disease or a GI event (eg, perforation, obstruction, or bleed) within 6 months before screening
Current use of any medication that may cause a clinically significant drug interaction when co-administered with diclofenac
Current use of any medication that might affect the pharmacokinetics of diclofenac
History of bleeding disorders .
Developmental delay or behavioral problems that would make it difficult to assess pain.
Impaired liver function
Clinically significant renal or cardiovascular disease
Any medical condition that compromises ability to swallow, absorb, metabolize, or excrete the study drug
Previously received any investigational product or device within 30 days before Screening or scheduled to receive an investigational device or another investigational drug (other than that in this study) during the course of this study.
Previous participation in this clinical study or currently taking diclofenac.